DBV Technologies Bolsters VITESSE Trial Results with Strong Comparative Data for Peanut Allergy Patch
Key Facts
- •Results showed 83% of children treated with the VIASKIN Peanut Patch increased their eliciting dose compared to 48% in the placebo group.
- •Approximately 60% of treated children increased their eliciting dose by at least two doses by month 12.
- •The VITESSE study is the largest food allergy immunotherapy trial to date, targeting children aged 4 to 7 years.
DBV Technologies presented detailed Phase 3 VITESSE trial data for its VIASKIN Peanut Patch during an oral presentation in Philadelphia, further strengthening its clinical profile. The findings showed that 83% of treated children increased their eliciting dose, significantly outperforming the 48% in the placebo group. Notably, 60% of treated subjects achieved a two-dose increase, compared to just 23% of those receiving the placebo. The patch also demonstrated a protective effect, with only 6.4% of treated subjects seeing a dose decrease versus 24% in the placebo group. As the largest food allergy immunotherapy trial to date, these results solidify the path toward regulatory submission for children aged 4 to 7. Listed on both Euronext Paris (DBV) and Nasdaq (DBVT), the company is now well-positioned for potential commercialization and significant future revenue growth.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis